Barclays
PGEN icon

Barclays’s Precigen PGEN Stock Holding History

Barclays’s Portfolio PGEN Stock Details PGEN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-100
Closed -$1K – 6390
2019
Q4 		$1K Sell
100
-1,400
-93% -$7.88K ﹤0.01% 6280
2019
Q3 		$9K Buy
1,500
+100
+7% +$679 ﹤0.01% 6372
2019
Q2 		$11K Sell
1,400
-2,600
-65% -$14K ﹤0.01% 6537
2019
Q1 		$21K Sell
4,000
-358,400
-99% -$2.48M ﹤0.01% 6345
2018
Q4 		$2.37M Buy
362,400
+359,100
+10,882% +$4.02M ﹤0.01% 2237
2018
Q3 		$57K Hold
3,300
– – ﹤0.01% 6002
2018
Q2 		$46K Sell
3,300
-12,200
-79% -$206K ﹤0.01% 5691
2018
Q1 		$238K Buy
15,500
+15,300
+7,650% +$219K ﹤0.01% 4680
2017
Q4 		$2K Buy
+200
New +$2.98K ﹤0.01% 6788
2017
Q1 		– Sell
-101
Closed -$2K – 6921
2016
Q4 		$2K Buy
+101
New +$2.81K ﹤0.01% 6364
2015
Q2 		– Sell
-104,633
Closed -$4.5M – 7154
2015
Q1 		$4.5M Buy
+104,633
New +$3.76M 0.01% 1646

Other funds holding PGEN

PCM
Patient Capital Management Baltimore, Maryland $3.05B AUM 42.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $948M AUM 47.49% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Barclays's PGEN Position: Q2 2026 in Review

Barclays increased its Precigen (PGEN) stake by 89% in Q2 2026, buying an estimated $1.9M and bringing the position to 931,368 shares worth $5.31M. The position accounts for ﹤0.01% of the portfolio, ranked #1804.

Barclays first reported a position in PGEN in Q3 2013 and has held it in 44 quarters since. The position peaked at $14.5M in Q3 2018. 210 funds tracked by Wall St. Rank hold PGEN as of Q2 2026.

  • Barclays held 931,368 shares of Precigen worth $5.31M as of Q2 2026.
  • Barclays bought 439,672 Precigen shares in Q2 2026, an estimated $1.9M.
  • Precigen made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #1804 holding.
  • Barclays first reported a position in Precigen in Q3 2013 and has held it in 44 quarters since.
  • Barclays's Precigen position peaked at $14.5M in Q3 2018.
  • 210 funds tracked by Wall St. Rank held Precigen as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.